Monday, September 23, 2019
- 1:45pm-3:15pm
-
Parkinson Kinetigraph – does it change the management of PD patients?
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Parkinson´s Disease, respiratory capacity and functionality: a Physical Therapy perspective
Physical and Occupational Therapy · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Parkinson’s disease patients with both GBA and LRRK2 mutations are phenotypically similar to LRRK2 – a possible protective effect?
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Parkinson’s disease in Middle East, North Africa and South Asia: Consensus from the MDS Task Force on the Middle East
Other · Agora 2 West, Level 2
- 1:45pm-3:15pm
-
Parkinson’s disease Polygenic Risk Factor Scores in Patients with Inflammatory Bowel Disease
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Parkinson’s Disease Treatments and Outcomes: US v Non-US Patients
Quality of Life · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Parkinsonism and other motor features in familial frontotemporal dementia with mutations in the MAPT, GRN, or C9orf72 gene (LEFFTDS cohort)
Genetics · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
Parotitis as Adverse Event Following BoNT Injections for Sialorrhea
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
Paroxysmal asymmetric dystonic arm posturing – a less recognised but characteristic manifestation of ATP1A3-related disease
Rare Genetic and Metabolic Diseases · Les Muses Terrace, Level 3
- «Previous Page
- 1
- …
- 48
- 49
- 50
- 51
- 52
- …
- 75
- Next Page»